- Home
- CTCX vs CHEK Comparison
CTCX vs CHEK Comparison
Compare CTCX & CHEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTCX
- CHEK
- Stock Information
- Founded
- CTCX 2007
- CHEK 2004
- Country
- CTCX United States
- CHEK Israel
- Employees
- CTCX N/A
- CHEK N/A
- Industry
- CTCX Medical/Dental Instruments
- CHEK Medical Electronics
- Sector
- CTCX Health Care
- CHEK Health Care
- Exchange
- CTCX Nasdaq
- CHEK Nasdaq
- Market Cap
- CTCX 10.4M
- CHEK 9.0M
- IPO Year
- CTCX N/A
- CHEK 2015
- Fundamental
- Price
- CTCX $0.32
- CHEK $0.90
- Analyst Decision
- CTCX
- CHEK
- Analyst Count
- CTCX 0
- CHEK 0
- Target Price
- CTCX N/A
- CHEK N/A
- AVG Volume (30 Days)
- CTCX 1.1M
- CHEK 1.1M
- Earning Date
- CTCX 03-31-2025
- CHEK 02-18-2025
- Dividend Yield
- CTCX N/A
- CHEK N/A
- EPS Growth
- CTCX N/A
- CHEK N/A
- EPS
- CTCX N/A
- CHEK N/A
- Revenue
- CTCX $32,839.00
- CHEK N/A
- Revenue This Year
- CTCX N/A
- CHEK N/A
- Revenue Next Year
- CTCX N/A
- CHEK N/A
- P/E Ratio
- CTCX N/A
- CHEK N/A
- Revenue Growth
- CTCX N/A
- CHEK N/A
- 52 Week Low
- CTCX $0.20
- CHEK $0.56
- 52 Week High
- CTCX $4.00
- CHEK $3.45
- Technical
- Relative Strength Index (RSI)
- CTCX 40.82
- CHEK 41.58
- Support Level
- CTCX $0.37
- CHEK $0.81
- Resistance Level
- CTCX $0.49
- CHEK $1.07
- Average True Range (ATR)
- CTCX 0.08
- CHEK 0.10
- MACD
- CTCX -0.02
- CHEK -0.07
- Stochastic Oscillator
- CTCX 0.84
- CHEK 12.28
About CTCX Carmell Corporation
Carmell Corp is a bio-aesthetics company that utilizes the Carmell Secretome to support skin and hair health. Its cosmetic skincare product portfolio includes Carmell G.L.E.E and various others in pipeline such as Youth restoring formula, Ultra-brightening formula, Ultra-hydrating formula, and Rapid Recovery formula among others. The company has one operating segment, principally the business of developing and commercializing bio-aesthetics and its bone and tissue healing products.
About CHEK Check-Cap Ltd.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.